Posts Archive

NCT05064787: Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy The aim of this...

The INSURE Study 2701 The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of Relapsed/Refractory Multiple Myeloma (RRMM)...

NCT05024045: Phase 1 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers The purpose of this study is to find out whether...

NCT04754100: Phase 1 - AGENT-797 in Participants With Relapsed/Refractory Multiple Myeloma This is a Phase 1, open-label study to ...

1676 Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician’s Choice in the Treatment of Patients with Relapsed or Refractory...

IGNITE STUDY - ALLO-605: IGNITE STUDY UTILIZING FIRST TurboCAR™ TO TARGET BCMA NCT05000450: Phase 1/2: Safety and Efficacy of ALLO-605 an...

NCT05153330: Phase 1: Study of BMF-219, in Adult Patients With Acute Leukemia, Diffuse Large B-Cell Lymphoma and Multiple Myeloma...

NCT05053607: Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma With Isatuximab NCT05053607: Real World...

NCT05136807: Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies NCT05136807: Quality of Life in Patients With...

NCT04772989: Phase 1: A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies A Study to Evaluate...

NCT05113342: Phase 1/2: Descartes-25 in Relapsed/Refractory Multiple Myeloma Descartes-25 in Relapsed/Refractory Multiple Myeloma This is...

PERK Inhibitor NCT05027594: Phase 1: Ph I Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Multiple Myeloma Ph I Study of...

MajesTEC-3 A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and...

NCT05139225: Phase 1: A Study of TTI-621 and TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma A...

The PCROWD Study invites people with precursor conditions to Share samples a few times each year when they are collected as part of...

Relapsed/refractory multiple myeloma with at least 3 prior lines of therapy NCT05090566: Phase 2: MagnetisMM-4: Umbrella Study of...

bb2121 Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma (KarMMa-7) KarMMa-7 Relapsed & Refractory Multiple...

NCT05121103: Phase 1: A Study in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma...

CARTITUDE-5 Phase 3 A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against...